References
- McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–3726.
- Castiglione V, Aimo A, Vergaro G, et al. Biomarkers for the diagnosis and management of heart failure. Heart Fail Rev. 2022;27(2):625–643.
- Storti S, Prontera C, Emdin M, et al. Analytical performance and clinical results of a fully automated MEIA system for brain natriuretic peptide assay: comparison with a point of care testing method. Clin Chem Lab Med. 2004;42:1178–1185.
- Rawlins ML, Owen WE, Roberts WL. Performance characteristics of four automated natriuretic peptide assays. Am J Clin Pathol. 2005;123(3):439–445.
- Wu AH, Packer M, Smith A, et al. Analytical and clinical evaluation of the Bayer ADVIA centaur automated B-type natriuretic peptide assay in patients with heart failure: a multisite study. Clin Chem. 2004;50(5):867–873.
- García de Guadiana-Romualdo L, Ramos-Arenas V, Campos-Rodríguez V, et al. In vitro stability of B-type natriuretic peptide (BNP) in plasma stored under different conditions when measured with the lumipulse® assay. Scand J Clin Lab Invest. 2019;79(6):455–458.
- Shah K, Terracciano GJ, Jiang K, et al. Comparability of results between point-of-care and automated instruments to measure B-type natriuretic peptide. West J Emerg Med. 2010;11:44–48.
- Kagiyama N, Kitai T, Hayashida A, et al. Prognostic value of BNP reduction during hospitalization in patients with acute heart failure. J Card Fail. 2019;25(9):712–721.
- Okamoto R, Ali Y, Hashizume R, et al. BNP as a major player in the heart-kidney connection. IJMS. 2019;20(14):3581.